Sonoma Pharmaceu SEC Filings

Sonoma Pharmaceuticals disclosed that Chief Executive Officer Amy Trombly received an equity grant in the form of restricted stock units (RSUs). On 01/02/2026, she was awarded 10,000 RSUs, each representing a contingent right to receive one share of Sonoma common stock. The RSUs vest on the third anniversary of the grant date, or earlier upon a change of control, aligning the CEO’s compensation with longer-term company performance. Following this grant, Ms. Trombly beneficially owns 42,185 derivative securities related to Sonoma stock in direct ownership.

Sonoma Pharmaceuticals, Inc. filed a report showing an equity award to one of its officers. On 01/02/2026, Controller John Dal Poggetto received 5,000 restricted stock units (RSUs), each representing a contingent right to receive one share of Sonoma common stock.

The RSUs vest on the third anniversary of the grant date or upon a change of control, according to the disclosure. Following this grant, Dal Poggetto directly beneficially owns 25,250 derivative securities tied to Sonoma common stock.

Sonoma Pharmaceuticals (SNOA) reported Q2 FY2026 results. Revenue was $5.604 million, up 57% year over year, with gross profit of $2.120 million and a gross margin of 38%. Net loss narrowed to $0.534 million (basic and diluted EPS $(0.32)) from a $0.610 million loss a year ago.

Six-month performance: Revenue reached $9.619 million, up 38% year over year, with gross profit of $3.584 million and a 37% margin. Operating expenses were $2.457 million in Q2 and $5.016 million for the first half.

Cash and liquidity: Cash and equivalents were $3.035 million at September 30, 2025, and net cash used in operating activities was $2.650 million for the six months. Working capital was $8.179 million. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern within one year without additional capital. Subsequent to quarter end, the company sold 51,436 shares via its at-the-market program for gross proceeds of $232,000 and net proceeds of $170,000. Shares outstanding were 1,701,076 as of November 3, 2025.

Sonoma Pharmaceuticals reported a leadership change. The company terminated Bruce Thornton as Executive Vice President and Chief Operating Officer, effective October 18, 2025. He also left any other positions at the company and its subsidiaries.

According to the disclosure, Mr. Thornton will receive only compensation and benefits earned through October 18, 2025. The filing did not state any additional payments. Sonoma’s common stock trades on Nasdaq under the symbol SNOA.

Sonoma Pharmaceuticals, Inc. is offering up to 492,967 shares of common stock in an at-the-market type offering at an example price of $4.20 per share. Prior to the offering there were 1,649,765 shares outstanding and the company states that up to 2,142,732 shares could be outstanding after the offering depending on sales price and authorization limits. Net proceeds are intended for working capital and general corporate purposes. The prospectus supplement discloses 105,500 RSUs outstanding that may dilute shareholders and shows a pro forma net tangible book value per share (adjusted for option exercises after June 30, 2025) of $2.47 with an increase attributable to the offering of $0.34 per share. The filing refers investors to the "Risk Factors" section and to incorporated reports including annual and quarterly reports and current reports filed in 2023 and 2025 for additional information.